Skip to main content

Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease.

Lee S, She J, Deng B, Kim J, de Andrade M, Na J, Sun Z, Wampfler JA, Cunningham JM, Wu Y, Limper AH, Aubry MC, Wendt C, Biterman P, Yang P, Lou Z
Oncotarget. 2016 Jul 12;7(28):44211-44223. doi: 10.18632/oncotarget.9954. (Link opens in a new window) PubMed (Link opens in a new window) Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.

Antibodies from Article